This is what Forbes are saying…
Enter Revive Therapeutics, a biotech company with its fingers in several pies: the emerging psychedelics industry, where it has a research partnership with the University of Wisconsin-Madison for formulation development and a clinical trial for substance use using psilocybin; the cannabis industry, where it has patented several unique cannabinoid delivery methods; and more recently, the market for coronavirus treatments, where it is one of fewer than 20 companies undertaking a phase 3 FDA trial—and the one with the lowest market cap.
Phase 3 Trial Currently Underway
“Right now, there’s a lot of interest in treatments,” said CEO Michael Frank by phone. “Vaccines are not necessarily here tomorrow. This virus comes with a lot of side effects, and the drug we have has a strong history and safety profile.”
The drug in question, bucillamine, is an anti-rheumatic, anti-inflammatory drug that has been used in Japan and South Korea to treat rheumatoid arthritis for more than 30 years. According to Frank, Revive repurposed the drug for the first time in 2015 and 2016 during a phase two clinical trial for gout. It is now being repurposed once again to target inflammation of the lungs caused by the virus. Revive is the only company currently studying the drug for this use, and expects to share preliminary data once analyzed, after the 210 interim patient point is reached.
In July, the company received approval from the U.S. Food and Drug Administration to conduct a randomized, double-blind, placebo-controlled phase 3 clinical trial to evaluate the safety and efficacy of the drug in patients with mild to moderate cases of Covid-19.
